|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Headache: The Journal of Head and Face PainVolume 45 Issue s1, Pages S57 - S65 Published Online: 5 Apr 2005 © 2010 American Headache Society Published on behalf of the American Headache Society
Abstract | References | Full Text: HTML, PDF (Size: 70K) | Related Articles | Citation Tracking  Topiramate in Migraine Prevention From the Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA. Copyright 2005 by the American Headache Society KEYWORDS topiramate • migraine • prevention (Headache 2005;45[Suppl 1]:S57-S65) ABSTRACTThe efficacy of topiramate in migraine prevention (prophylaxis) was established in two multicenter, randomized, double-blind, placebo-controlled, pivotal trials. Topiramate has received regulatory approval for use in adults for migraine prophylaxis (prevention) in the US and numerous other countries, including France, Ireland, Switzerland, Brazil, Taiwan, Spain, and Australia. Treatment with 100 or 200 mg per day of topiramate was associated with significant reductions in the frequency of migraine headaches, number of migraine days, and use of acute medications. No increase in efficacy was observed between 100 and 200 mg per day of topiramate. Based on efficacy and tolerability, 100 mg per day of topiramate should be the initial target dose for most patients. The most common adverse events were paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease, and taste perversion. Topiramate is a first-line migraine preventive drug and should especially be considered as a preferred treatment for all patients who are concerned about gaining weight, who are currently overweight, or who have coexisting epilepsy. | 
|
